Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 26, 2023, Calliditas Therapeutics announced the availability of its 2022 Annual Report on the company's website. The report provides insights into the company's performance, including developments in their lead product, Nefecon, which received FDA accelerated approval as TARPEYO® and conditional marketing authorization in the EU as Kinpeygo®. Additionally, Calliditas is advancing clinical trials for its NOX inhibitor product candidate, setanaxib, targeting primary biliary cholangitis and head & neck cancer. Contact for investor relations is Åsa Hillsten, available via phone or email. The company cautioned that the report contains forward-looking statements that are subject to risks and uncertainties regarding future performance.